上市保荐书 华泰联合证券有限责任公司 关于湖北振华化学股份有限公司 向不特定对象发行可转换公司债券并在主板上市 之上市保荐书 上海证券交易所： 作为湖北振华化学股份有限公司（以下简称"发行人""公司""振华股 份"）申请向不特定对象发行可转换公司债券并在主板上市的保荐人，华泰联合 证券有限责任公司（以下简称"华泰联合证券"、"保荐人"）及其保荐代表人已 根据《中华人民共和国公司法》《中华人民共和国证券法》《证券发行上市保荐业 务管理办法》《上市公司证券发行注册管理办法》（以下简称"《再融资注册办 法》"）《上海证券交易所上市公司证券发行上市审核规则》等法律法规和中国 证监会及贵所的有关规定，诚实守信，勤勉尽责，严格按照依法制定的业务规则 和行业自律规范出具上市保荐书，并保证所出具文件真实、准确、完整。 现将有关情况报告如下： 一、发行人基本情况 （一）发行人概况 1、公司名称：湖北振华化学股份有限公司 2、注册地址：湖北省黄石市西塞山区黄石大道 668 号 3、设立日期：2003 年 6 月 19 日 4、注册资本： 509,016,166 元 5、法定代表人：蔡再华 6、联系方式：86-0714-64063 ...

股票简称：振华股份 股票代码：603067 湖北振华化学股份有限公司 （Hubei Zhenhua Chemical CO., LTD.） （注册地址：湖北省黄石市西塞山区黄石大道 668 号） 向不特定对象发行可转换公司债券 并在主板上市募集说明书 （修订稿） （深圳市前海深港合作区南山街道桂湾五路128号前海深港基金小镇B7栋401） 二〇二三年八月 保荐人（主承销商） 声 明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对申请 文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的 盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与之相反 的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由发 行人自行负责。投资者自主判断发行人的投资价值，自主作出投资决策，自行承 担证券依法发行后因发行人经营与收益变化或者证券价格变动引致的投资风险。 1-1-2 重大事项提示 本公司特别提请投资者注意，在作出投资决策之前，务必仔细阅读本募集说 明书正文内容，并特别关注以下重要事项。 一、关于本次可转换公司债券发行符合发行条件的说明 根据 ...

上海市锦天城律师事务所 关于湖北振华化学股份有限公司 2023 年度向不特定对象发行可转换公司债券的 补充法律意见书（一） | 正 文 3 | | --- | | 问题 1、关于本次募投项目必要性 3 | | 问题 7、关于环保情况 30 | 地址：上海市浦东新区银城中路 501 号上海中心大厦 11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 补充法律意见书 上海市锦天城律师事务所 关于湖北振华化学股份有限公司 2023 年度向不特定对象发行可转换公司债券的 补充法律意见书（一） 案号：01F20230173 致：湖北振华化学股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受湖北振华化学股份有限 公司（以下简称"发行人"、"公司"或"振华股份"）的委托，并根据发行人与 本所签订的《专项法律顾问聘请合同》，作为发行人在上海证券交易所（以下简 称"上交所"）向不特定对象发行可转换公司债券项目（以下简称"本次发行"） 的特聘专项法律顾问，已于 2023 年 6 月 19 日出具了《上海市锦天城律师事务所 关于湖北振华化学股份有限公 ...

证券代码：603067 证券简称：振华股份 公告编号：2023-034 湖北振华化学股份有限公司 关于参加 2023 年湖北辖区上市公司投资者网上 集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为便于广大投资者全面了解湖北振华化学股份有限公司（以下简称"公司"） 业绩、公司治理、经营状况、可持续发展等投资者所关心的问题，加强公司与投 资者之间的沟通交流，公司将参加由湖北证监局、湖北省上市公司协会与深圳市 全景网络有限公司联合举办的"提高发展质量 切实回报股东"——2023 年湖北 辖区上市公司投资者网上集体接待日主题活动。 现将有关事项公告如下：本次活动将在深圳市全景网络有限公司提供的网上 平台，采用网络远程的方式举行，投资者可登录"全景路演"网站 (https://rs.p5w.net)，或关注微信公众号：全景财经，或下载全景路演 APP，参与 本次互动交流，活动时间为 2023 年 5 月 25（周四）14:30-16:35。 出席本次集体接待日活动的人员有：公司财务总监、董事会秘书杨帆先生， ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥849,988,097.42, representing a year-on-year increase of 7.56%[5] - The net profit attributable to shareholders for the same period was ¥101,952,932.44, with a growth of 2.40% compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥105,384,424.90, reflecting a 4.60% increase year-on-year[5] - Total operating revenue for Q1 2023 was ¥849,988,097.42, an increase of 7.5% compared to ¥790,212,377.27 in Q1 2022[19] - Net profit for Q1 2023 was ¥99,404,376.82, slightly down from ¥99,696,464.50 in Q1 2022, representing a decrease of 0.3%[20] - Earnings per share for Q1 2023 remained stable at ¥0.20, consistent with Q1 2022[21] - The net profit for Q1 2023 was CNY 49,168,262.46, up 7.2% from CNY 45,535,566.29 in Q1 2022[30] Cash Flow and Liquidity - The net cash flow from operating activities decreased significantly by 62.83%, amounting to ¥39,514,062.12[5] - Cash inflow from operating activities in Q1 2023 was CNY 474,820,064.91, a decrease of 28.7% compared to CNY 665,044,192.64 in Q1 2022[24] - Net cash flow from operating activities in Q1 2023 was CNY 39,514,062.12, down 62.9% from CNY 106,318,988.57 in Q1 2022[24] - Cash and cash equivalents decreased by 46.77% due to reduced cash flow from operating activities[9] - Cash and cash equivalents at the end of Q1 2023 were CNY 131,926,723.07, slightly down from CNY 133,436,983.90 at the end of Q1 2022[25] - The cash and cash equivalents at the end of Q1 2023 were CNY 28,273,577.38, down from CNY 84,621,091.19 at the end of Q1 2022[33] Assets and Liabilities - The total assets at the end of the reporting period were ¥4,051,461,372.44, an increase of 1.76% from the end of the previous year[6] - The company's total liabilities as of March 31, 2023, were ¥1,390,883,150.33, a decrease from ¥1,424,979,052.98 at the end of 2022[18] - The total assets as of March 31, 2023, were ¥4,051,461,372.44, up from ¥3,981,262,232.97 at the end of 2022[18] - The total liabilities decreased to CNY 1,200,788,011.49 in Q1 2023 from CNY 1,224,384,454.81 in Q4 2022, a reduction of approximately 2.0%[28] - Current liabilities as of March 31, 2023, were CNY 820,534,281.54, a decrease from CNY 849,082,401.94 as of December 31, 2022[27] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 29,394[10] - The top shareholder held 37.16% of the shares, while the second-largest shareholder held 3.59%[11] Research and Development - Research and development expenses for Q1 2023 were ¥21,619,303.74, down from ¥27,318,027.86 in Q1 2022, indicating a reduction of 20.9%[19] - Research and development expenses for Q1 2023 were CNY 13,899,689.05, slightly down from CNY 14,072,711.31 in Q1 2022[30] Operational Changes - The company reported a 92.71% decrease in asset disposal income, indicating a decline in asset sales[9] - The company's long-term equity investments decreased from RMB 3,222,940.52 to RMB 2,993,729.24, a decline of about 7.10%[16] - The company reported a significant increase in accounts payable, rising to RMB 230,126,255.89 from RMB 180,317,965.20, an increase of approximately 27.63%[16] - The company has not disclosed any new product developments or market expansion strategies in the current report[14] - The company plans to continue focusing on market expansion and new product development in the upcoming quarters[34]

证券代码：603067 证券简称：振华股份 公告编号：2023-021 湖北振华化学股份有限公司 关于召开 2022 年度业绩暨现金分红说明会的公告 信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 04 月 13 日(星期四) 上午 09:00-10:00 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 04 月 06 日(星期四) 至 04 月 12 日(星期 三)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 603067@hszhenhua.com 进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答。 湖北振华化学股份有限公司（以下简称"公司"）已于 2023 年 3 月 31 日发布公司 2022 年度报告，为便于广大投资者更全 ...

Financial Performance - The company's operating revenue for 2022 was CNY 3,533,800,546.53, representing an 18.06% increase compared to CNY 2,993,229,140.68 in 2021[27]. - Net profit attributable to shareholders for 2022 was CNY 416,969,678.03, a 34.22% increase from CNY 310,669,589.76 in 2021[27]. - The basic earnings per share for 2022 was CNY 0.83, up 31.75% from CNY 0.63 in 2021[28]. - The total assets at the end of 2022 were CNY 3,981,262,232.97, a 12.70% increase from CNY 3,532,775,476.07 at the end of 2021[27]. - The cash flow from operating activities for 2022 was CNY 490,978,501.71, reflecting a 20.35% increase from CNY 407,943,586.11 in 2021[27]. - The company achieved operating revenue of 3.53 billion RMB in 2022, an increase of 18.06% year-on-year, and a net profit attributable to shareholders of 417 million RMB, up 34.22% year-on-year[56]. - The total assets of the company reached 3.98 billion RMB at the end of 2022, growing by 12.70% year-on-year, while the equity attributable to shareholders increased by 16.56% to 2.52 billion RMB[56]. Dividend and Shareholder Value - The company plans to distribute a cash dividend of 2.07 CNY per 10 shares, totaling 105,366,346.36 CNY, which represents 25.27% of the net profit attributable to shareholders for the year[7]. - The company emphasizes the importance of maintaining shareholder value, particularly for small and medium investors, through its profit distribution strategy[7]. - The cash dividend for the reporting period is CNY 93,548,574.55, which represents 30.11% of the net profit attributable to ordinary shareholders in the consolidated financial statements[183]. - The company has established a cash dividend policy that respects and protects shareholder interests, ensuring a scientific, sustainable, and stable return mechanism[180]. Market Position and Operations - The company is the largest and most comprehensive producer of chromium chemicals and vitamin K3 globally, indicating strong market positioning[7]. - The company is engaged in the research, production, and sales of chromium chemicals and related products, highlighting its focus on core business development[7]. - The company is the largest producer of chromium salts globally and has the highest production capacity for Vitamin K3[50]. - The company has established a unique "full-process circular economy and resource utilization system" in the chromium salt industry, enhancing its competitive edge[48]. - The company has successfully integrated its production bases in Hubei and Chongqing, optimizing product transportation and reducing costs[50]. Research and Development - The company applied for 9 patents through its subsidiary, showcasing its technological capabilities and market potential despite a downturn in the lithium battery electrolyte market[39]. - The company has applied for a total of 118 patents, with 68 granted, including 47 invention patents and 17 utility model patents[104]. - The company’s R&D expenses rose by 28.49% to 106 million RMB, reflecting a commitment to innovation and product development[58]. - The company has established a research reward fund to incentivize technical personnel for significant contributions to innovation[102]. Environmental and Sustainability Initiatives - The company emphasizes clean production technologies and has developed unique capabilities in comprehensive utilization of chromium-containing waste[44]. - The company is committed to advancing its green manufacturing capabilities and resource utilization efficiency as part of its long-term strategy[88]. - The company has implemented a comprehensive waste management strategy, including the treatment and storage of chromium-containing waste[197]. - The company reported no exceedance of emission standards for SO2, NOx, and particulate matter in its waste gas emissions[192]. Governance and Compliance - The board of directors has confirmed that all members attended the board meeting, ensuring governance and oversight[5]. - The company has implemented a governance structure that includes a board of directors and supervisory board to ensure compliance with legal requirements[151]. - The company will continuously optimize its corporate governance structure to further protect the rights and interests of investors, especially small and medium-sized investors[153]. - The company has received a standard unqualified opinion on its internal control audit for the 2022 financial report[190]. Strategic Investments and Future Plans - The company aims to achieve a revenue target of CNY 3.92 billion and a net profit of CNY 480 million in 2023, indicating a focus on growth and profitability[137]. - The company plans to enhance its supply chain and resource allocation, with an automated sorting device for chromium ore expected to be operational in the first half of 2023[133]. - The company is actively exploring opportunities in the new energy long-duration storage sector, with its flow battery electrolyte products entering engineering practice and commercialization[54]. - The company will issue convertible bonds to support its expansion into emerging markets and optimize by-product value[139].

2021 年年度报告 公司代码：603067 公司简称：振华股份 湖北振华化学股份有限公司 2021 年年度报告 1 / 213 2021 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 大信会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人蔡再华、主管会计工作负责人杨帆及会计机构负责人（会计主管人员）周芬芬声 明：保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 本次利润分配拟以方案实施前的公司总股本508,416,166股为基数，每10股派发现金红利1.84 元（含税），共计派发现金红利93,548,574.55元（含税）。上述现金分红比例为占年度归属于上 市公司股东的净利润的30.11%。 六、 前瞻性陈述的风险声明 √适用 □不适用 本年度报告内容中涉及的未来计划、发展战略等前瞻性陈述因存在不确定性，不构成公司对 投资者的实质承诺， ...

2022 年第一季度报告 证券代码：603067 证券简称：振华股份 湖北振华化学股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同期增减 | | --- | --- | --- | | | | 变动幅度(%) | | 营业收入 | 790,212,377.27 | 18.36 | | 归属于上市公司股东的净利润 | 99,560,159.82 | 173.25 | | 归属于上市公司股东的扣除非经常 | 100,751,740.13 | 187.71 | ...